BeStock  
Stocks › Biotechnology › VRDN

Viridian Therapeutics VRDN

US equityMarket cap rank #2344Biotechnology
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±10.5%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+49.4%
Worst reaction-17.2%

Stock move on the day after each report

-16.7%2019/Q4+7.3%2020/Q1-6.8%2020/Q2+4.7%2020/Q4+5.5%2021/Q4+28.0%2022/Q1+49.4%2022/Q2-0.9%2022/Q3-10.5%2022/Q4-1.2%2023/Q1-1.6%2024/Q1+15.5%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q34 Nov 2026Pre Market±17.6%+15.53%Within range
2024/Q18 May 2024Pre Market±13.1%-1.59%Within range
2023/Q19 May 2023After Market±22.8%-1.21%Within range
2022/Q48 Mar 2023Pre Market±15.9%-10.48%Within range
2022/Q314 Nov 2022Pre Market±19.9%-0.93%Within range
2022/Q215 Aug 2022Pre Market–+49.36%–
2022/Q112 May 2022None±11.4%+28.03%Bigger than priced
2021/Q410 Mar 2022None±23.6%+5.46%Within range
2020/Q425 Mar 2021After Market–+4.75%–
2020/Q25 Aug 2020None–-6.84%–
2020/Q17 May 2020None–+7.27%–
2019/Q411 Mar 2020After Market–-16.65%–
2019/Q37 Nov 2019After Market–+0.55%–
2019/Q27 Aug 2019After Market–-17.20%–
2019/Q18 May 2019After Market–+0.00%–
2018/Q413 Mar 2019After Market–+2.64%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$25.75M-63.5% YoY
Operating profit-$103.48M-158.6% YoY
Net profit-$101.21M-192.5% YoY
Diluted EPS-$0.81-138.2% YoY
Free cash flow-$103.14M-21.7% YoY
Operating cash flow-$92.77M

Revenue, last 8 quarters

$72.0KDec '24$72.0KMar '25$75.0KJun '25$70.6MSep '25$132.0KDec '25$141.0KMar '26$284.0KJun '26$25.8MSep '26

Net profit, last 8 quarters

$-79.7MDec '24$-86.9MMar '25$-100.7MJun '25$-34.6MSep '25$-120.4MDec '25$-104.9MMar '26$-127.1MJun '26$-101.2MSep '26

Profitability & balance sheet

Gross margin94.1%
Operating margin-1,781.4%
Net margin-1,741.9%
Return on equity-115.0%
Return on assets-57.1%
Return on invested capital-88.1%
Current ratio14.46
Liabilities / assets43.5%
Cash & investments$955.21M
Total debt$242.46M
Net cash (debt)$712.75M

Discussion

No comments yet — be the first to weigh in on VRDN.

Sign in to join the discussion.

Scroll to Top